WIRTJES SEAN M 4

What Happened Sean M. Wirtjes, Chief Financial Officer of Rapid Micro Biosystems, was granted a total of 290,000 award shares on February 11, 2026: 97,000 restricted stock units (RSUs) and 193,000 derivative award shares (option-type award). Both grants are reported at $0.00 per share (no cash paid at grant). These are compensation awards, not open-market purchases or sales.

Key Details

• Transaction date: February 11, 2026; Form 4 filed February 13, 2026 (timely, 2 days after transaction).
• Grants: 97,000 RSUs (reported as A, acquired) and 193,000 derivative award shares (reported as A, derivative). Total = 290,000 shares.
• Vesting (per footnotes): RSUs vest in three annual installments — 33.4% on the first anniversary of the Feb 11, 2026 grant date (approx. Feb 11, 2027) and 33.3% on each of the second and third anniversaries, subject to continued service. The derivative award vests in 48 substantially equal monthly installments, with the first installment vesting on March 11, 2026.
• Shares owned after the transaction: not specified in the filing.
• No indication of sale, tax withholding, 10b5-1 plan, or late filing in the submitted Form 4.

Context These awards are standard equity compensation for an executive and do not represent an open-market purchase (a stronger signal of personal investment). RSUs deliver shares upon vesting, while the derivative award vests monthly over four years — both subject to continued employment.